Drug Trial Radar · NCT03193190
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
341
Actual
Start
Jul 5, 2017
Primary completion
Feb 27, 2025
Study completion Feb 27, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jun 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of patients who have received no prior systemic therapy for metastatic PDAC, and Cohort 2 will consist of patients who have received one line of prior systemic therapy for PDAC. In each cohort, eligible patients will be assigned to one of several treatment arms.
Conditions
- Pancreatic Adenocarcinoma
Interventions
Nab-PaclitaxelDrug
Nab-Paclitaxel will be administered as per the schedule specified in the respective arm.
GemcitabineDrug
Gemcitabine will be administered as per the schedule specified in the respective arm.
OxaliplatinDrug
Oxaliplatin will be administered as per the schedule specified in the respective arm.
LeucovorinDrug
Leucovorin will be administered as per the schedule specified in the respective arm.
FluorouracilDrug
Fluorouracil will be administered as per the schedule specified in the respective arm.
AtezolizumabDrug
Atezolizumab will be administered as per the schedule specified in the respective arm.
CobimetinibDrug
Cobimetinib will be administered as per the schedule specified in the respective arm.
PEGPH20Drug
PEGPH20 will be administered as per the schedule specified in the respective arm.
BL-8040Drug
BL-8040 will be administered as per the schedule specified in the respective arm.
SelicrelumabDrug
Selicrelumab will be administered as per the schedule specified in the respective arm.
BevacizumabDrug
Bevacizumab will be administered as per the schedule specified in the respective arm.
RO6874281Drug
RO6874281 will be administered as per the schedule specified in the respective arm
AB928Drug
AB928 will be administered as per the schedule specified in the respective arm.
TiragolumabDrug
Tiragolumab will be administered as per the schedule specified in the respective arm.
TocilizumabDrug
Tocilizumab will be administered as per the schedule specified in the respective arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stage 1: Percentage of Participants With Objective Response (OR), as Determined by Investigator According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)Time frame: Up to 33.3 months
Locations
23 sites in 5 countries. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California
Helen Diller Fam Comp Can Ctr
San Francisco, California
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut
Lombardi Cancer Center, Georgetown University
Washington D.C., District of Columbia
Uni of Chicago Medical Center
Chicago, Illinois
Dana-Farber Cancer Institute
Boston, Massachusetts
MorristownMedicalCenter
Morristown, New Jersey
Columbia University
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Oregon Health and Science University
Portland, Oregon
Hillman Cancer Center
Pittsburgh, Pennsylvania
Medical College of Wisconsin
Milwaukee, Wisconsin
Universitätsklinikum Essen
Essen, Germany
National Cancer Center Hospital East
Chiba, Japan
Kanagawa Cancer Center
Kanagawa, Japan
National Cancer Center Hospital
Tokyo, Japan
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Hospital Universitario Vall d Hebron
Barcelona, Spain
Hosp. G. U Gregorio Marañón
Madrid, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
Clínica Universidad de Navarra
Pamplona, Navarre, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.